The Alzheimer's Disease State team is focused on helping discover new medicines for the treatment of the disease. Key leaders have been recruited and on boarded, faculty, and staff and are building foundational capabilities and workflows.
Researchers are studying how the body's own immune system may impact the underlying biology associated with cognitive decline, the primary symptom of Alzheimer's disease. The team is planning to establish new immune biomarkers associated with Alzheimer's disease that together, with existing Alzheimer's biomarkers, will help better predict onset and progression. Once determined, researchers will investigate and develop immune-based therapies that not only positively influence biomarkers of the disease, but that are also tailored precisely to an individual’s own biology.